Canadian Cancer Trials Group Bulletins

Trial Management Group

Trial Activation

Canadian Cancer Trials Group IND.215 - A Phase Ib Study of Selumetinib in Patients with Previously Treated or Untreated Advanced/Metastatic NSCLC who are Receiving Standard Chemotherapy Regimens - was centrally activated on January 30, 2013.

The primary objective of this trial is to determine the recommended phase II dose (RP2D) and safety profile of selumetinib in patients with advanced/metastatic NSCLC in combination with:

- Pemetrexed
- Pemetrexed and cisplatin
- Paclitaxel and carboplatin.